Things are well and truly on track for clinical stage pharmaceutical company Pharmaxis (ASX: PXS), a sentiment confirmed by CEO Gary Phillips in his shareholder address in their recent quarterly results. The Company has made significant progress in three clinical trial programs, with plenty on the horizon for their preclinical pipeline too. Lead asset PXS-5505
Read More
In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with research into their anti-fibrotic drug pipeline. For those unfamiliar with their work, Pharmaxis is developing drugs based on their proprietary amine-oxidase technology. These drugs work by inhibiting an enzyme pathway that is key in the
Read More
Just days after closing their oversubscribed $9.8 million capital raise, drug developer Pharmaxis (ASX: PXS) has seen further funding devoted to its projects, this time from the Government to apply work towards skin diseases and pancreatic cancer. The NMHRC Drug Development Grant scheme is an Australian government initiative set up to provide financial aid to
Read More
When the University of Rochester came knocking on the door of biopharmaceutical company Pharmaxis (ASX: PXS), it was a boost from a respected group of researchers for their lead drug candidate PXS-5505 which has continued to draw attention from around the world. By agreement with Pharmaxis, the University of Rochester embarked on preclinical work on
Read More
Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the
Read More